Drugs / LErafAON
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00024661 | Mar 2001 → Oct 2004 | neoplasm | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT00024648 | Mar 2001 → Dec 2004 | neoplasm | INSYS Therapeutics Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LErafAON | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00024648 ↗ |
| Action | Inhibit | “in vivo inhibition of Raf-1 protein by LErafAON.” NCT00024661 ↗ |
| Modality | Antisense oligonucleotide | “LErafAON is a liposome encapsulated c-raf antisense oligonucleotide.” NCT00024648 ↗ |
| Route | Intravenous | “Patients with advanced malignancies will receive daily IV infusions of LErafAON for 2 weeks” NCT00024648 ↗ |